Benralizumab is noninferior to mepolizumab in achieving remission of relapsing or refractory eosinophilic granulomatosis with polyangiitis at 36 and 48 weeks, according to data published in The ...

BOSTON — Patients taking benralizumab experienced more asthma exacerbations than patients taking mepolizumab, according to an abstract presented at the CHEST Annual Meeting. This study ...

Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed ...

Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if it was used to treat acute asthma attacks.

Researchers have shown that the drug benralizumab is as effective and safe as mepolizumab for inducing remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) according to ...

At the recent American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, researchers reported that treatment with benralizumab (Fasenra) was noninferior to mepolizumab (Nucala) for ...

However, the results suggest that "long-term benralizumab-driven 318 eosinophil depletion results in disrupted airway luminal occlusions and improved airway structure and function," which may ...

Although both benralizumab and mepolizumab were associated with a decline in eosinophil counts, a deeper, more significant reduction was observed in the benralizumab treatment arm at all 3 time ...

The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Gastroenterology > General Gastroenterology Benralizumab Led to Histologic Responses in Eosinophilic Esophagitis — But there was no significant difference in symptom relief compared with placebo ...

Read the side effects of Benralizumab as described in the medical literature. In case of any doubt consult your doctor or pharmacist.